Irbezyd H can be taken once daily, with or without food.
Dose titration with the individual components (i.e. irbesartan and hydrochlorothiazide) may be recommended.
When clinically appropriate direct change from monotherapy to the fixed combinations may be considered: Irbezyd H 150 mg/12.5 mg may be administered in patients whose blood pressure is not adequately controlled with hydrochlorothiazide or irbesartan 150 mg alone; Irbezyd H 300 mg/12.5 mg may be administered in patients insufficiently controlled by irbesartan 300 mg or by Irbezyd H 150 mg/12.5 mg.
When necessary, Irbezyd H may be administered with another antihypertensive medicinal product.
Renal impairment: due to the hydrochlorothiazide component, Irbezyd H is not recommended for patients with severe renal dysfunction (creatinine clearance <30 ml/min). Loop diuretics are preferred than thiazides in this population. No dosage adjustment is necessary in patients with renal impairment whose renal creatinine clearance is >30 ml/min.
Hepatic impairment: Irbezyd H is not indicated in patients with severe hepatic impairment. Thiazides should be used with caution in patients with impaired hepatic function. No dosage adjustment of Irbezyd H is necessary in patients with mild to moderate hepatic impairment.
Elderly patients: no dosage adjustment of Irbezyd H is necessary in elderly patients.
Paediatric patients: Irbezyd H is not recommended for use in children and adolescents due to a lack of data on safety and efficacy.